Synergistic effects of sonoporation and taurolidin/TRAIL on apoptosis in human fibrosarcoma.

Adrien Daigeler, Ansgar M Chromik, Kathrin Haendschke, Sabine Emmelmann, Monica Siepmann, Karin Hensel, Georg Schmitz, Ludger Klein-Hitpass, Hans U Steinau, Marcus Lehnhardt, Joerg Hauser, Adrien Daigeler, Ansgar M. Chromik, Kathrin Haendschke, Sabine Emmelmann, Monica Siepmann, Karin Hensel, Georg Schmitz, Ludger Klein-Hitpass, Hans U. Steinau, Marcus Lehnhardt, Joerg Hauser

Index: Ultrasound Med. Biol. 36(11) , 1893-906, (2010)

Full Text: HTML

Abstract

Sonodynamic therapy, in combination with ultrasound contrast agents, proved to enhance the uptake of chemotherapeutics in malignant cells. HT1080 fibrosarcoma cells were treated in vitro with a combination of ultrasound SonoVue™-microbubbles and taurolidine (TRD) plus tumor necrosis factor related apoptosis inducing ligand (TRAIL). Apoptosis was measured by TdT-mediated dUTP-biotin nick end labelling (TUNEL) assay and fluorescence activated cell sorting (FACS) analysis. Gene expression was analysed by RNA-microarray. The apoptotic effects of TRD and TRAIL on human fibrosarcoma are enhanced by sonodynamic therapy and additional application of contrast agents, such as SonoVue™ by 25%. A broad change in the expression of genes related to apoptotic pathways is observed when ultrasound and microbubbles act synchronously in combination with the chemotherapeutics (e.g. BIRC3, NFKBIA and TNFAIP3). Some of these genes have already been proven to play a role in programmed cell death in human fibrosarcoma (HSPA1A/HSPA1B, APAF1, PAWR, SOCS2) or were associated with sonication induced apoptosis (CD44). Further studies are needed to explore the options of sonodynamic therapy on soft tissue sarcoma and its molecular mechanisms.Copyright © 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.